Orforglipron (Foundayo) is the first oral non-peptide GLP-1 receptor agonist, FDA-approved April 2026. Cannabis interaction data is currently absent — what the evidence suggests.
Foundayo (orforglipron, oral)+Cannabis / THC
🔵
Insufficient Data — Monitor
Orforglipron + Cannabis (THC/CBD)
Orforglipron (Foundayo) was FDA-approved in April 2026. No cannabis interaction data exists for this medication. Based on its GLP-1 mechanism and oral route, caution around edible cannabis and GI side effects is warranted pending clinical evidence.
What This Means
In Plain Language
Orforglipron is a first-in-class oral, non-peptide GLP-1 receptor agonist. Unlike semaglutide and tirzepatide (which are injectable peptides), orforglipron is a small-molecule drug taken daily by mouth. Its GLP-1 mechanism includes gastric emptying delay similar to injectable GLP-1 medications. This creates theoretical edible cannabis timing concerns. However, as a newly approved medication (April 2026), no cannabis interaction studies exist. This profile applies conservative clinical reasoning in the absence of data.
Clinical Considerations
Key Risks & Factors
Newly approved medication — no cannabis interaction data: Foundayo received FDA approval in April 2026. No clinical data on cannabis co-administration exists. This profile is based on mechanistic reasoning.
Oral route introduces CYP interaction considerations: Unlike injectable semaglutide, orforglipron is an oral small-molecule drug. Its metabolic pathway (CYP3A4 substrate) means CYP interactions are more relevant than with injectable GLP-1 medications.
CBD and CYP3A4 considerations: High-dose CBD is a known CYP3A4 inhibitor, which could theoretically affect orforglipron blood levels. At OTC CBD doses this risk is low, but worth noting.
Gastric emptying delay and edible timing: As a GLP-1 agonist, orforglipron is expected to delay gastric emptying, creating edible cannabis timing concerns similar to other GLP-1 medications.
GI side effects: Orforglipron's known GI side effects (nausea, diarrhea) may compound cannabis-related GI effects.
Conservative Safety Assessment
Given orforglipron's recent approval, this 'Monitor' rating reflects the absence of cannabis interaction data rather than confirmed safety or harm. The mechanistic considerations above suggest monitoring is appropriate. As clinical experience accumulates, this profile will be updated. Reviewed and audited by Sanford A. Orloff, RPh (ret).
Enter all your medications, supplements, and lifestyle substances to see a complete pharmacist-reviewed interaction report — free, no account required.
Pharmacist-reviewed · FDA & NIH sources only · Always free
👨⚕️
Sanford A. Orloff, RPh (ret)
Registered Pharmacist · 40+ Years Clinical Experience · NPI 1518289974
Every interaction profile on InteractSafe is reviewed for editorial accuracy by a retired pharmacist with over 40 years of clinical experience in medication therapy management, patient counseling, and pharmaceutical care.
No cannabis interaction data exists for orforglipron as of June 2026. As a GLP-1 agonist, it shares the gastric-emptying-delay concern that affects edible cannabis timing with other GLP-1 medications. Additionally, as an oral small-molecule CYP3A4 substrate, high-dose CBD may theoretically affect its blood levels. Discuss cannabis use with your prescribing physician.
No comparative data exists. The absence of cannabis interaction data for orforglipron does not imply it is safer than semaglutide or tirzepatide with cannabis — it simply means this specific combination has not been studied yet. Apply the same caution as with other GLP-1 medications.
This profile is for educational purposes only. Reviewed for editorial accuracy by Sanford A. Orloff, RPh (ret).
It is NOT medical advice and does not replace consultation with a licensed physician or pharmacist.
Never change your medication routine based on this information alone.
Read Full Safety Terms →